Study: Moderna, Merck vaccines could cut melanoma's recurrence by 44 percent

Moderna vaccine
(Image credit: (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images))

There could be light at the end of the tunnel for individuals battling melanoma cancer. CBS News reported that researchers conducted a study to develop a "potential skin cancer vaccine" from Merck and Moderna, and found some promising results.

According to Reuters, a combination of Moderna's experimental melanoma vaccine and Merck's immunotherapy Keytruda "cut the risk of skin cancer's recurrence or death by 44 percent compared with Keytruda alone in a mid-stage trial."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Kelsee Majette, The Week US

Kelsee Majette has worked as a social media editor at The Week since 2022. In 2019, she got her start in local television as a digital producer and fill-in weather reporter at NTV News. Kelsee also co-produced a lifestyle talk show while working in Nebraska and later transitioned to 13News Now as a digital content producer.